Auris Medical Announces Acquisition of RNA Therapeutics Company and Plans for Strategic Repositioning
June 03, 2021 07:30 ET
|
Auris Medical AG
Entering field of RNA therapeutics through acquisition of Trasir Therapeutics, Inc.Trasir’s innovative peptide-based OligoPhoreTM platform designed to enable extrahepatic delivery of...
miRecule Inc. closes $5.7 M to Create Breakthrough RNA Therapies for Cancer and Muscular Dystrophy
May 27, 2021 11:07 ET
|
miRecule
GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has...
NapaJen Pharma Reports Positive Results from Phase 1 Clinical Trial of Novel RNA Interference (RNAi) Therapeutic
October 08, 2020 07:35 ET
|
NapaJen
NJA-730 is an Anti-CD-40 Oligonucleotide Combined with Beta-Glucan Delivery Vehicle with Potential to Treat Acute Graft-versus-Host Disease (aGvHD) Treatment Shown to be Safe and Well-Tolerated...
Oligonucleotide Synthesis Market Worth $3.9 Billion by 2025, Growing at a CAGR of 10.4% from 2019- Global Opportunity Analysis and Industry Forecasts by Meticulous Research®
June 16, 2020 08:55 ET
|
Meticulous Market Research Pvt. Ltd.
London, June 16, 2020 (GLOBE NEWSWIRE) -- The oligonucleotide synthesis market is expected to grow at a CAGR 10.4% from 2019 to 2025 to reach $3.9 billion by 2025. Oligonucleotide-based therapy and...
NapaJen Pharma and Astellas Pharma Establish Research Collaboration for Discovery and Development of Novel Oligonucleotides
March 18, 2019 07:35 ET
|
NapaJen
BURLINGAME, Calif. and TOKYO, March 18, 2019 (GLOBE NEWSWIRE) -- NapaJen Pharma, Inc., a biotherapeutics company leveraging its proprietary oligonucleotide delivery technology to develop novel...
NapaJen Pharma Announces First Patient Dosed in Phase 1 First-in-Human Clinical Trial of Novel RNA Interference (RNAi) Therapeutic
November 15, 2018 07:35 ET
|
NapaJen
NJA-730 is an Anti-CD-40 Small Interfering RNA (siRNA) Combined with Beta-Glucan Delivery Vehicle with Potential to Treat Acute Graft-versus-Host Disease Program Leverages NapaJen’s Immune...
MDRNA, Inc. Appoints James M. Karis to Its Board of Directors
August 11, 2009 09:15 ET
|
MDRNA, Inc.
BOTHELL, WA--(Marketwire - August 11, 2009) - MDRNA, Inc. (NASDAQ: MRNA) announced today that
James M. Karis has been appointed to the Company's Board of Directors. His
appointment brings the number...